Fig. 1

Potential effects of GLP-1RAs and SGLT2 inhibitors in CV outcomes trials. Based on the results from recent CV outcomes trials with GLP-1RAs and SGLT2 inhibitors, in addition to some common favorable CV effects associated with both classes, different class-specific effects (GLP-1RAs: benefit for risk of atherosclerotic outcomes, SGLT2 inhibitors: benefit for risk of HF outcomes) largely contributed to the overall improvement of CV outcomes. CV cardiovascular, GLP-1RA glucagon-like peptide-1 receptor agonist, SGLT2 sodium-glucose cotransporter 2